Granulomatosis Polyangiitis Presented with Diabetes Insipidus
Granülomatöz Polianjitisin Nadir Bir Tutulumu: Diabetes İnsipidus Olgusu

Emine KOCA, Emine Figen TARHAN*, Funda DINÇ ELİBOL**, Neşe ÇINAR***
Muğla Sıtkı Koçman University Faculty of Medicine, Department of Internal Medicine, Muğla, Turkey
*Muğla Sıtkı Koçman University Faculty of Medicine, Department of Rheumatology, Muğla, Turkey
**Muğla Sıtkı Koçman University Faculty of Medicine, Department of Radiology, Muğla, Turkey
***Muğla Sıtkı Koçman University Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Muğla, Turkey

Abstract
The pathogenesis of granulomatosis polyangiitis (GPA), systemic vasculitis of small and medium-size vessels, is not completely understood. GPA mainly affects the upper and lower respiratory tract. However, it may involve the central nervous system (CNS) as well. The most common manifestation of CNS involvement is necrotizing vasculitis, leading to peripheral neuropathies or cranial nerve palsies. CNS disorder is less common. CNS involvement in GPA can manifest itself in three ways: Vasculitic involvement, granuloma spread from adjacent anatomical areas, and new granuloma formation in brain tissue. We present a case of GPA presented with diabetes insipidus.

Keywords: Diabetes insipidus; pituitary insufficiency; granulomatosis polyangiitis; vasculitis

Özet
Granülomatöz polianjitis (GPA), küçük ve orta ölçekli damarların sistemik bir vaskülitidir. Patogenezi tam olarak anlaşılmasını gösterir. Başlıca üst ve alt solunum yolları etkiler. Ancak, sinir sistemi tutulumu da söz konusudur. En sik olarak, periferal neuropatileri veya kraniyal sinir felcine yol açan nekrotizan vaskülit olmak üzere kendini gösterir. Sinir sistemi (SSS) bozukluğu da az siklikta görülür. SSS tutulumu 3 şekilde olabilir: Vaskülitik tutulum, komşu anatomik alanlardan granülom yayılımı ve beyin dokusunda yeni granülom oluşumu. Biz bu olgumuzda, diabetes insipidus ile prezante olan bir GPA vakası sunduk.

Anahtar kelimeler: Diabetes insipidus; pitüiter yetmezlik; granülomatöz polianjitis; vaskülit

Introduction
Granulomatosis polyangiitis (GPA) is a systemic disease characterized by small vascular vasculitis of unknown etiology. GPA is involved in the class of vasculitis associated with antineutrophil cytoplasmic antibodies (ANCAs). It generally involves the upper and lower respiratory tract, kidneys, ear, nose, and throat. However, GPA may affect any organ or tissue (1). Diabetes insipidus (DI) is a rare, water homeostasis disorder characterized by abnormal hypotonic urinary excretion. Polyuric symptoms start developing if >90% of the

Address for Correspondence: Emine KOCA, Muğla Sıtkı Koçman University Faculty of Medicine, Department of Internal Medicine, Muğla, Turkey
Phone: +90 252 214 13 23 E-mail: emine_koca@hotmail.com.tr

This is an open access article under the CC BY-NC-SA license (https://creativecommons.org/licenses/by-nc-sa/4.0/)

DOI: 10.25179/tjem.2019-7145
vasopressinergic neurons in the supraoptic and paraventricular nuclei of the posterior pituitary get damaged (2).

Pituitary dysfunction is one of the rare findings of GPA. DI is the most common presentation of pituitary involvement in GPA (3). Ahlstrom et al. reported the first case in 1953 (4). Since then, only case reports or small case series have been published (5-10). In this case report, we review pituitary involvement, which is an extremely rare presentation of GPA.

Case Report
In March 2017, a 24-year-old woman was admitted to the Mugla Sitki Kocman University Department of Endocrinology and Metabolism Disorders with complaints of headache, polydipsia, and polyuria for about 3 years. Her vital signs were as follows: temperature 36.7°C, heart rate 90/min, and arterial blood pressure 100/80 mmHg. Her physical examination was normal. Her serum sodium level was 141.9 mmol/L and urine density was 1003 g/L. A water deprivation test was performed and the results were consistent with central DI. Table 1 shows the patient’s levels of the anterior pituitary hormone. Her adrenocorticotropic hormone (ACTH) level was 24.4 pg/mL (7.2-63.3 pg/mL) and cortisol level was 4.49 µg/dL (6.2-19.4 µg/dL). The results of the Synacthen stimulation test showed that cortisol values at 30 and 60 min were 17.27 and 11.94 µg/dL, respectively (<18-20 µg/dL is significant for diagnosis). Sella magnetic resonance imaging (MRI) showed a complex cystic lesion, 13×15×10 mm, with a 7x5 mm cystic part, extending to the suprasellar region. There was no compression of the optic chiasm and a bright spot of the neurohypophysis was not observed (Figure 1, Figure 2). Trans-sphenoidal pituitary surgery was performed and histopathological examination revealed granulomatous necrotizing vasculitis. For the differential diagnosis of granulomatous necrotizing vasculitis; the following tests were performed: C-reactive protein 39.6 mg/L (normal; <5 mg/L) and first hour sedimentation value 26 mm/h (<17 mm/h). Antinuclear antibody, anti dsDNA, anti-centromere antibody, antiJo-1, anti-Scl-70, anti-Sm, anti-SSA and -SSB, rheumatoid factor, antiphospholipid antibodies, anticardiolipin antibodies, and lupus anticoagulant were all negative. Moreover, her angiotensin-converting enzyme level for sarcoidosis was 25.40 U/L, which was in the normal range of 8-52 U/L, and purified protein derivative (PPD) test for tuberculosis was also negative. Her cytoplasmic antineutrophilic cytoplasmic antibodies (c-ANCA) were positive (70.4 and 98.4 U/mL, normal <20 U/mL) and perinuclear antineutrophilic cytoplasmic antibodies (p-ANCA) were neg-

| Blood Test | Result | Normal Range |
|------------|--------|--------------|
| ACTH (pg/mL) | 24.4 | 7.2-63.3 |
| CORTISOL (µg/dL) | 4.49 | 6.2-19.4 |
| TSH (µIU/mL) | 1.61 | 0.27-4.2 |
| FT4 (pmol/L) | 20.87 | 12-22 |
| FT3 (pmol/L) | 5.44 | 3.1-6.8 |
| FSH (mIU/mL) | 5.43 | 3.5-12.5 |
| LH (mIU/mL) | 13.15 | 2.4-12.6 |
| ESTRADIOL (pg/mL) | 125.5 | 12.4-233 |
| PROLACTIN (ng/mL) | 55.63 | 4.79-23.3 |
| GH (ng/mL) | <0.03 | 0.126-9.88 |

**Table 1. Results of the endocrine tests.**

ACTH: Adrenocorticotropic hormone, TSH: Thyroid-stimulating hormone, FT4: Free T4, FT3: Free T3, FSH: Follicle-stimulating hormone, LH: Luteinizing hormone, GH: Growth hormone.
In the paranasal sinus tomography, mucosal thickening in the ethmoid cells in the right maxillary sinus, erosions in the inferior part and the sellar region of the sphenoid sinus, soft tissue formation filling the sphenoid sinus, and focal defect in the central section of the nasal septum were observed (Figure 3, Figure 4). Thoracic tomography showed an asymmetric ice-glass density of 8 mm in diameter in the right upper lobe apical, focal thickening of the left upper lobe posterior fissure, and subpleural nodular density of 2 mm in the posterior lobe of the left lung. The patient was started on 1 mg/kg/day prednisolone and 15 mg/week methotrexate. One month after the beginning of the treatment, there was a considerable improvement in the symptoms of polyuria and polydipsia. Sedimentation value (5 mm/h) and C-reactive protein level (0.4 mg/L) were in the normal range after the treatment.

Discussion

GPA is a rare autoimmune disease characterized by necrotizing granulomatous vasculitis. Although it may frequently involve the upper and lower respiratory tract and kidneys, GPA may affect any other organ or tissue (1). Neurological involvement is seen in one-third of patients with GPA, mainly as a peripheral neuropathy due to small vessel vasculitis, and specifically, CNS involvement is seen in 7-18% of all GPA cases (2). Pituitary involvement in GPA, identified in 1953, is a rare condition and can be seen in about 1% of all GPA cases (3,4). There are some other diseases in the differential diagnosis of the granulomatous pituitary lesions such as idiopathic giant cell granulomatosis, sarcoidosis, Crohn’s disease, tuberculosis, and Takayasu vasculitis (11).

The pathophysiology of pituitary involvement in GPA and all related mechanisms have not been accurately described, but three primary reasons seem responsible. The most common reason is the direct intracranial extension of granulomatous process from the nose or paranasal granuloma to the pituitary gland. The second prevailing reason is the vasculitis of pituitary vessels and the third is granuloma development in the pituitary gland (5,12). Symptoms of pituitary insufficiency uncommonly co-occur with GPA but these symptoms are
generally combined with the clinical symptoms, months or years after diagnosis. These symptoms may be nonspecific, such as fatigue, weakness, or headache, and this may lead to a delay in diagnosis (1). Our case, unlike the literature, was diagnosed with GPA with the observation of pituitary insufficiency symptoms. Out of the 23 cases of pituitary involvement in GPA that were reviewed, in 8 cases, clinical features related to pituitary involvement were present at onset and preceded other organ involvement in 3 patients (13). Of these 8 cases, only one had isolated pituitary involvement at presentation, while in the other 7 cases, at least one other organ was involved (13). In one of the studies reviewed, the mean age at the time of diagnosis of pituitary insufficiency was 38 years and 74% of the patients were women (13). In the French Vasculitis Study Group cohort, nine patients with GPA had a mean age of 51 years (24-77 years) at the time of diagnosis, and 5 of these patients were women (1). Kapoor et al. found that the male to female ratio was equal and the average age at the time of diagnosis was 48 years among 8 cases (3). A clinical manifestation usually occurs in the form of DI or isolated anterior pituitary insufficiency (6-10). De Parisot et al. reported that the most common endocrinopathy in GPA is secondary hypogonadism (78%) followed by DI (71%) (1). A decrease in gonadotropin-releasing hormone secretion can be related to other pathophysiological mechanisms such as malnutrition, hyperprolactinemia, acute illness, or use of drugs (1). The mechanisms behind hypogonadism are still unclear. Treatment with glucocorticoids and cyclophosphamide suppresses the hypothalamic-pituitary-gonadal axis (14). Other hormonal pathologies in GPA-associated pituitary dysfunction are not as common as hypogonadism and DI. Some other hormone diseases may be reported as follows: central hypothyroidism in 54% of patients, secondary adrenal insufficiency in 39%, hyperprolactinemia in 37%, and growth hormone deficiency in 20% (1). The most common finding in MRI is pituitary gland enlargement. Other findings seen in MRI include cystic changes, infundibular thickening, and increased contrast enhancement. Another significant finding is the lack of characteristic hyperintense signal in T1 imaging (13). In our case, there was a 13×15×10 mm noncontrast lesion in the sellar cavity with a 7×5 mm complicated cystic nodule in the cranial part of the lesion. The remission induction therapy in GPA involves high-dose glucocorticoids combined with oral or intravenous cyclophosphamide (3). In the literature review of De Parisot et al., 69% of the patients were treated with conventional treatment and after five years of follow-up and 11% had a recurrent systemic disease (1). Induction therapy without using cyclophosphamide is related to recurrence in 50% of patients (3). Patients who are resistant to conventional treatment can be effectively treated with rituximab (15). GPA patients treated with rituximab achieve complete remission more frequently than those treated with cyclophosphamide but the experience of treatment with rituximab in GPA is limited (16). The follow-up of patients should include the evaluation of pituitary imaging and pituitary deficiency. In spite of the remission of systemic disease and the regression of radiological findings, the regeneration capacity of the pituitary function is limited because of the irreversible damage caused by necrotizing granulomatous lesions (1,3,13).

GPA is a vasculitic disease that may cause multiple organ dysfunction. Pituitary involvement is rarely seen in GPA. In the case of anterior or posterior pituitary insufficiency in a patient with a histopathological diagnosis of granulomatous necrotizing vasculitis of the pituitary masses, pituitary GPA should be considered in the differential diagnosis of the disorder.

Source of Finance
During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest
No conflicts of interest between the authors and / or family members of the sci-
entific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Authorship Contributions
Idea/Concept: Emine Koca, Emine Figen Tarhan, Neşe Çinar; Design: Emine Koca, Emine Figen Tarhan, Neşe Çinar; Control/Supervision: Emine Koca, Emine Figen Tarhan, Neşe Çinar; Data Collection and/or Processing: Emine Koca, Emine Figen Tarhan, Neşe Çinar, Funda Dinç Elibol; Analysis and/or Interpretation: Emine Koca, Emine Figen Tarhan, Neşe Çinar; Literature Review: Emine Koca, Emine Figen Tarhan, Neşe Çinar; Critical Review: Emine Koca, Neşe Çinar; References and Fundings: Emine Koca, Emine Figen Tarhan, Neşe Çinar.

References
1. De Parisot A, Puechal X, Langrand C, Raverot G, Gil H, Perard L, Le Guenno G, Berthier S, Tschirret O, Eschard JP, Vinzio S, Guillevin L, Sève P; French Vasculitis Study Group. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. Medicine (Baltimore). 2015;94:e748. [Crossref] [PubMed] [PMC]
2. Garrahy A, Moran C, Thompson CJ. Diagnosis and management of central diabetes insipidus in adults. Clin Endocrinol (Oxf). 2019;90:23-30. [Crossref] [PubMed]
3. Kapoor E, Cartin-Ceba R, Specks U, Leavitt J, Erickson B, Erickson D. Pituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic Experience. J Clin Endocrinol Metab. 2014;99:3988-3994. [Crossref] [PubMed] [PMC]
4. Ahlstrom CG, Liedholm K, Truedsson E. Respiratory-renal type of polyarteritisnodoso. Acta Med Scand. 1953;144:332-333. [Crossref] [PubMed]
5. Katzman GL, Langford CA, Sneller MC, Koby M, Patronas NJ. Pituitary involvement by Wegener’s granulomatosis: a report of two cases. AJNR Am J Neuroradiol. 1999;20:519-523. [PubMed]
6. Garovic VD, Clarke BL, Chilson TS, Specks U. Diabetes insipidus and anterior pituitary insucency as presenting fe tures of Wegener’s granulomatosis. Am J Kidney Dis. 2001;37:E5. [Crossref] [PubMed]
7. Mieszen WM, Janssens EN, van Bommel EF. Diabetes insipidus as the presenting symptom of Wegener’s granulomatosis. Nephrol Dial Transplant. 1999;14:426-429. [Crossref] [PubMed]
8. Tappouni R, Burns A. Pituitary involvement in We- gener’s granulomatosis. Nephrol Dial Transplant. 2000;15:2057-2058. [Crossref] [PubMed]
9. Haynes BF, Fauci AS. Diabetes insipidus associated with Wegener’s granulomatosis successfully treated with cyclophosphamide. N Engl J Med. 1978;299:764. [Crossref] [PubMed]
10. Rosete A, Cabral AR, Kraus A, Alarcón-Segovia D. Diabetes insipidus secondary to Wegener’s granulomatosis: report and review of the literature. J Rheumatol. 1991;18:761-765. [PubMed]
11. Carpinteri R, Patelli I, Casanueva FF, Giustina A. Pituitary tumours: in ammatory and granulomatous expansive lesions of the pituitary. Best Pract Res Clin Endocrinol Metab. 2009;23:639-650. [Crossref] [PubMed]
12. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993;33:4-9. [Crossref] [PubMed]
13. Yong TY, Li JY, Amato L, Mahadevan K, Phillips PJ, Coates PS, Coates PT. Pituitary involvement in We- gener’s granulomatosis. Pituitary. 2008;11:77-84. [Crossref] [PubMed]
14. Arnaud L, Nordin A, Lundholm H, Svenungsson E, Hellbacher E, Wikner J, Zickert A, Gunnarsson I. Effect of corticosteroids and cyclophosphamide on sex hormone profiles in male patients with systemic lupus erythematosus and systemic sclerosis. Arthritis Rheumatol. 2017;69:1272-1279. [Crossref] [PubMed]
15. Cartin-Ceba R, Fervenza FC, Specks U. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr Opin Rheumatol. 2012;24:15-23. [Crossref] [PubMed]
16. Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U; RAVE-ITN Research Group. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75:1166-1169. [Crossref] [PubMed] [PMC]